Natamycin

證據等級: L5

預測適應症: 10 個

Natamycin: From Fungal Keratitis to Vulvovaginal Candidiasis

One-Sentence Summary

Natamycin is a polyene macrolide antifungal agent, globally established for treating ophthalmic fungal infections (fungal keratitis) and topical candidiasis, but currently not registered in India. The TxGNN model predicts it may be highly effective for Vulvovaginal Candidiasis (VVC), with 1 completed Phase 3 clinical trial and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	No India registration; globally used for fungal keratitis and topical candidiasis
Predicted New Indication	Vulvovaginal Candidiasis
TxGNN Prediction Score	99.97%
Evidence Level	L1
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Natamycin is a polyene macrolide antifungal that binds with high affinity to ergosterol — the principal sterol in fungal cell membranes. This binding forms transmembrane channels that disrupt ionic gradients, ultimately causing fungal cell death. Because ergosterol is absent in mammalian cells (which use cholesterol instead), this mechanism confers high selectivity for fungi with a favourable systemic safety profile.

Vulvovaginal candidiasis is caused predominantly by Candida albicans (accounting for 85–90% of cases), whose cell membrane is rich in ergosterol — precisely the molecular target of natamycin. The mechanistic link is therefore direct, specific, and biologically well-established. Furthermore, vaginal topical delivery achieves high local drug concentrations while systemic absorption remains negligible, making this route particularly well-suited to VVC treatment.

Globally, natamycin vaginal suppositories (marketed as Pimafucin®) have been used for vaginal candidiasis in Europe and other regions for over five decades. A recently completed Phase 3 RCT (NCT06411314, 2023, n=218) confirmed the efficacy of the natamycin/lactulose combination — with results published in 2025 (PMID 39979898). The TxGNN prediction therefore aligns closely with established international clinical evidence; the primary objective for India is market entry rather than de novo mechanistic repurposing.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06411314	Phase 3	Completed	218	International RCT comparing Natamycin 100 mg + Lactulose 300 mg vaginal suppositories vs. Natamycin 100 mg alone (Pimafucin) vs. Lactulose 300 mg alone in non-pregnant adult females with VVC. The combination arm demonstrated superior efficacy; safety also assessed. Results published in BMC Women’s Health (2025).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39979898	2025	RCT (Phase 3)	BMC Women’s Health	Natamycin + Lactulose vaginal suppositories assessed for efficacy and safety in adult females with VVC; direct highest-level evidence for natamycin-based vaginal formulation
4561566	1972	RCT	Medical Journal of Australia	Comparative trial of natamycin pessaries vs. amphotericin B pessaries in vaginal candidiasis; established early head-to-head clinical efficacy of natamycin
6760652	1982	Clinical Trial	Acta Obstetricia et Gynecologica Scandinavica	33 patients treated with natamycin vaginal tablets for 10 days; cure rate 88–94% at 1-month follow-up; partner co-treatment did not significantly improve outcomes
159686	1979	Clinical Trial	ANZ Journal of Obstetrics and Gynaecology	Controlled trial (n=120) comparing lytic enzyme preparation (Elase) plus natamycin vs. natamycin alone in monilial vulvovaginitis; combination improved both symptom alleviation and organism eradication
1082689	1975	Clinical Trial	Zentralblatt für Gynäkologie	Combination of oral metronidazole and vaginal natamycin tablets in mixed urogenital infections; Candida vaginal mycoses cured clinically in 89% of patients after the first treatment course
6972554	1981	Clinical Study	Przeglad Dermatologiczny	Multiple natamycin formulations evaluated in cutaneous and mucosal multifocal candidiasis including vaginal sites; supports broad-spectrum mucosal antifungal activity
6966774	1980	Clinical Study	New Zealand Medical Journal	50 women with vaginal C. albicans treated with natamycin vaginal tablets twice nightly for 10 days; 76% cure rate at 2 weeks, maintained at 4-week follow-up
4545913	1972	Clinical Observation	Sbor. Věd. Pr. LF UK Hradec Králové	Clinical experience treating gynaecological candidiasis and trichomoniasis with natamycin; supports gynaecological antifungal use
11048415	1999	Review	Česká Gynekologie	Review of diagnostics and treatment of chronic vaginal candidiasis; direct comparison of natamycin vs. clotrimazole, supporting natamycin as a clinically effective option
41412769	2025	Survey	Česká a Slovenská Farmacie	Survey of VVC management in Ukraine (n=408); lifetime VVC prevalence 72.6%; vaginal itching and cottage cheese-like discharge were the most common symptoms; contextualises current clinical practice and natamycin’s role

India Market Information

Natamycin currently has no registered products in India. There are no approved licenses, authorised formulations, or recorded market history in the Indian regulatory system as of the data cut-off date (2026-04-04). A de novo CDSCO market authorisation application will be required before commercial use is possible.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 3 RCT (NCT06411314, n=218, published 2025) directly demonstrates natamycin’s efficacy in vulvovaginal candidiasis, and the drug has a decades-long international safety and efficacy record under the brand Pimafucin®. The mechanistic basis (selective ergosterol-binding against Candida species) is well-characterised and directly applicable to VVC, and local vaginal delivery minimises systemic exposure. The primary barrier to use in India is the absence of local registration, not a lack of clinical evidence.

To proceed, the following is needed:

Preparation and submission of a full regulatory dossier to CDSCO (Central Drugs Standard Control Organisation) for market authorisation in India
Download and parsing of full package insert to complete mandatory safety assessment (key warnings, contraindications — Data Gap DG001)
Retrieval of detailed mechanism of action data via DrugBank API (Data Gap DG002)
Design of a local pharmacovigilance plan aligned with CDSCO requirements
Clarification of appropriate dosage form strategy for the Indian market (vaginal suppositories vs. tablets) and assessment of import/local manufacturing pathway
Consideration of special population data (pregnancy safety: case-control evidence available, PMID 12849848) for labelling purposes
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.